The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
Bertrand F. Tombal
Consultant or Advisory Role - Astellas Pharma; Medivation
Research Funding - Astellas Pharma
Other Remuneration - Astellas Pharma; Medivation
Michael Borre
No relevant relationships to disclose
Per Rathenborg
No relevant relationships to disclose
Patrick Werbrouck
No relevant relationships to disclose
Hendrik Van Poppel
No relevant relationships to disclose
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi
Honoraria - Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Ipsen; Janssen-Cilag; Pfizer; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi
Peter Iversen
Consultant or Advisory Role - Ferring; Janssen; Sanofi
Honoraria - Astellas Pharma; Medivation
Johan Braeckman
No relevant relationships to disclose
Jiri Heracek
No relevant relationships to disclose
Edwina Baskin-Bey
Employment or Leadership Position - Astellas Pharma (U)
Taoufik Ouatas
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
De Phung
Employment or Leadership Position - Astellas Pharma
Mohammad Hirmand
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Matthew Raymond Smith
Consultant or Advisory Role - Astellas Pharma; Janssen; Millennium
Research Funding - Astellas Pharma; Janssen; Millennium